Analysts Anticipate United Therapeutics Co. (NASDAQ:UTHR) Will Post Earnings of $2.31 Per Share

Share on StockTwits

Wall Street analysts forecast that United Therapeutics Co. (NASDAQ:UTHR) will report earnings per share of $2.31 for the current quarter, according to Zacks. Five analysts have made estimates for United Therapeutics’ earnings. The highest EPS estimate is $3.13 and the lowest is $1.88. United Therapeutics reported earnings per share of $3.98 in the same quarter last year, which suggests a negative year over year growth rate of 42%. The company is expected to announce its next earnings report on Wednesday, October 30th.

According to Zacks, analysts expect that United Therapeutics will report full-year earnings of ($1.96) per share for the current year, with EPS estimates ranging from ($3.73) to ($0.50). For the next fiscal year, analysts expect that the firm will post earnings of $9.36 per share, with EPS estimates ranging from $7.62 to $11.74. Zacks’ EPS averages are an average based on a survey of analysts that cover United Therapeutics.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported $4.66 earnings per share for the quarter, topping the consensus estimate of $2.40 by $2.26. The firm had revenue of $373.60 million during the quarter, compared to analysts’ expectations of $331.78 million. United Therapeutics had a negative return on equity of 4.54% and a negative net margin of 7.69%.

A number of equities research analysts have weighed in on UTHR shares. Zacks Investment Research cut United Therapeutics from a “buy” rating to a “hold” rating and set a $86.00 price objective for the company. in a research note on Wednesday, August 14th. Credit Suisse Group upgraded United Therapeutics from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $98.00 to $101.00 in a research note on Monday, July 1st. Jefferies Financial Group upgraded United Therapeutics from an “underperform” rating to a “hold” rating and set a $90.00 price objective for the company in a research note on Thursday, August 1st. LADENBURG THALM/SH SH upgraded United Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $103.00 to $106.00 in a research note on Thursday, August 1st. Finally, ValuEngine upgraded United Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company’s stock. United Therapeutics has an average rating of “Hold” and a consensus target price of $121.73.

Shares of NASDAQ UTHR opened at $82.14 on Friday. The company has a current ratio of 4.62, a quick ratio of 4.41 and a debt-to-equity ratio of 0.31. United Therapeutics has a twelve month low of $74.31 and a twelve month high of $128.94. The stock has a 50 day moving average of $81.73 and a two-hundred day moving average of $86.46. The stock has a market cap of $3.58 billion, a P/E ratio of 6.13 and a beta of 0.95.

Several large investors have recently added to or reduced their stakes in UTHR. Pearl River Capital LLC acquired a new position in shares of United Therapeutics in the second quarter valued at approximately $32,000. Private Ocean LLC acquired a new position in shares of United Therapeutics in the second quarter valued at approximately $34,000. NEXT Financial Group Inc increased its holdings in shares of United Therapeutics by 72.7% in the second quarter. NEXT Financial Group Inc now owns 475 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 200 shares during the period. Machina Capital S.A.S. increased its holdings in shares of United Therapeutics by 776.4% in the second quarter. Machina Capital S.A.S. now owns 964 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 854 shares during the period. Finally, Tower Research Capital LLC TRC increased its holdings in shares of United Therapeutics by 1,023.3% in the second quarter. Tower Research Capital LLC TRC now owns 1,831 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 1,668 shares during the period. 94.37% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Further Reading: Does the discount rate affect the economy?

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

National Bank Financial Analysts Increase Earnings Estimates for DHX Media Ltd.
National Bank Financial Analysts Increase Earnings Estimates for DHX Media Ltd.
Schwab U.S. Large-Cap Growth ETF  Stock Holdings Increased by Schneider Downs Wealth Management Advisors LP
Schwab U.S. Large-Cap Growth ETF Stock Holdings Increased by Schneider Downs Wealth Management Advisors LP
Grimes & Company Inc. Acquires Shares of 26,659 Medtronic PLC
Grimes & Company Inc. Acquires Shares of 26,659 Medtronic PLC
Schneider Downs Wealth Management Advisors LP Buys New Shares in ANSYS, Inc.
Schneider Downs Wealth Management Advisors LP Buys New Shares in ANSYS, Inc.
Grimes & Company Inc. Increases Position in Albemarle Co.
Grimes & Company Inc. Increases Position in Albemarle Co.
Oracle Co.  Shares Bought by Grimes & Company Inc.
Oracle Co. Shares Bought by Grimes & Company Inc.


 
© 2006-2019 Zolmax.